3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Phase 1
1
Status
Completed
4
Withdrawn
3
Unknown
1
Active not recruiting
1
Sponsor Class
OTHER
3
Study Type
Interventional
3
Sponsor
Cancer Type
NET
3
Endocrine
3
CNS
2
Gastrointestinal
1
Conditions
Neuroendocrine Tumors
3
Pheochromocytoma
1
Paraganglioma
1
Gastro-enteropancreatic neuroendocrine tumor
1
Interventions
telotristat ethyl
3
lutetium Lu 177 dotatate
3
3-Iodobenzylguanidine
3
177Lu-octreotide, DOTA(0)-Tyr(3)-
2
veliparib
1
vandetanib
1
pasireotide
1
gallium Ga 68 dotatate
1
Tretinoin
1
Temozolomide
1
Isotretinoin
1
Introns
1
Everolimus
1
Diazoxide
1
Capecitabine
1
177Lu-octreotate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Withdrawn
×
3-Iodobenzylguanidine
×
NET
×
Clear all
NCT04614766
2024-04-29
SPORE-3
University of Iowa
Phase 1/2
Withdrawn
NCT04831567
2022-05-19
MIBNET
AC Camargo Cancer Center
Phase 2
Withdrawn
NCT01941849
2015-12-21
VIBRaNT
University College, London
Phase 1
Withdrawn